Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Telitacicept 240mg
DRUG
3 trials
Sponsors
RemeGen Co., Ltd.
, Ruijin Hospital
, Zhongming Qiu
Conditions
Glucocorticoid
IgA Nephropathy
IgA Nephropathy (IgAN)
Inflammatory Myopathy
Kidney Diseases
Telitacicept
Phase 2
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
Terminated
NCT04905212
RemeGen Co., Ltd.
IgA Nephropathy
Start: 2021-11-04
End: 2023-11-09
Updated: 2023-12-06
TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)
Not yet recruiting
NCT07355257
Zhongming Qiu
Inflammatory Myopathy
Start: 2026-02-02
End: 2027-03-30
Target: 30
Updated: 2026-01-21
Unknown Phase
Efficacy and Safety of Telitacicept in IgAN
Recruiting
NCT06654596
Ruijin Hospital
Glucocorticoid, IgA Nephropathy (IgAN), Kidney Diseases +1
Start: 2024-12-06
End: 2026-12-31
Target: 118
Updated: 2025-01-01
Related Papers
Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study
CNS Neuroscience & Therapeutics
2022-07-18
31 citations